BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 38765008)

  • 1. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
    Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
    Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in sarcomas: a systematic review.
    Anastasiou M; Kyriazoglou A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Giannopoulou A; Kosmidou A; Smerdi D; Moutafi M; Gavrielatou N; Psyrri A
    Immunooncol Technol; 2023 Dec; 20():100407. PubMed ID: 38192615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab.
    Kantarjian HM; Logan AC; Zaman F; Gökbuget N; Bargou RC; Zeng Y; Zugmaier G; Locatelli F
    Ther Adv Hematol; 2023; 14():20406207231201454. PubMed ID: 37822571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
    Blay JY; Chevret S; Le Cesne A; Brahmi M; Penel N; Cousin S; Bertucci F; Bompas E; Ryckewaert T; Soibinet P; Boudou-Rouquette P; Saada Bouzid E; Soulie P; Valentin T; Lotz JP; Tosi D; Neviere Z; Cancel M; Ray-Coquard I; Gambotti L; Legrand F; Lamrani-Ghaouti A; Simon C; Even C; Massard C
    Lancet Oncol; 2023 Aug; 24(8):892-902. PubMed ID: 37429302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
    Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
    Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
    Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
    Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
    Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
    Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-cell infiltration in high-grade soft tissue sarcomas; prognostic implications of tumor-associated macrophages and B-cells.
    Nyström H; Jönsson M; Nilbert M; Carneiro A
    Acta Oncol; 2023 Jan; 62(1):33-39. PubMed ID: 36786033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
    Dai L; Guo X; Xing Z; Tao Y; Liang W; Shi Z; Hu W; Zhou S; Wang X
    BMC Cancer; 2023 Jan; 23(1):102. PubMed ID: 36717836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
    J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Dickinson MJ; Carlo-Stella C; Morschhauser F; Bachy E; Corradini P; Iacoboni G; Khan C; Wróbel T; Offner F; Trněný M; Wu SJ; Cartron G; Hertzberg M; Sureda A; Perez-Callejo D; Lundberg L; Relf J; Dixon M; Clark E; Humphrey K; Hutchings M
    N Engl J Med; 2022 Dec; 387(24):2220-2231. PubMed ID: 36507690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
    Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
    BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma.
    Hagelstein I; Engel M; Hinterleitner C; Manz T; Märklin M; Jung G; Salih HR; Zekri L
    Front Immunol; 2022; 13():1002898. PubMed ID: 36275693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor resistance in soft tissue sarcoma.
    Eulo V; Van Tine BA
    Cancer Drug Resist; 2022; 5(2):328-338. PubMed ID: 35800372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
    Zhang S; Black RG; Kohli K; Hayes BJ; Miller C; Koehne A; Schroeder BA; Abrams K; Schulte BC; Alexiev BA; Heimberger AB; Zhang A; Jing W; Ng JCK; Shinglot H; Seguin B; Salter AI; Riddell SR; Jensen MC; Gottschalk S; Moore PF; Torok-Storb B; Pollack SM
    Mol Cancer Ther; 2022 Jun; 21(6):999-1009. PubMed ID: 35405743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany.
    Kajüter H; Wellmann I; Khil L; Jöckel KH; Zhang C; Fink AM; Hallek M; Stang A
    Blood Cancer J; 2021 Oct; 11(10):174. PubMed ID: 34716290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H3/CD276: An Emerging Cancer Immunotherapy.
    Zhou WT; Jin WL
    Front Immunol; 2021; 12():701006. PubMed ID: 34349762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of CD276 in Cancers.
    Liu S; Liang J; Liu Z; Zhang C; Wang Y; Watson AH; Zhou C; Zhang F; Wu K; Zhang F; Lu Y; Wang X
    Front Oncol; 2021; 11():654684. PubMed ID: 33842369
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.